IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Duft, *et al.*

Serial No.: 09/445,517

Filed: June 5, 1998

For: METHOD FOR TREATING OBESITY

Group Art Unit: 1645

Examiner: Devi, S.

TRANSMITTAL LETTER

Commissioner for Patents
Washington, D.C. 20231

Sir:

Enclosed are the following documents:

- Transmittal Letter
- Information Disclosure Statement
- PTO Form 1449
- Copies of 76 cited references
- Return Postcard

CERTIFICATE OF MAILING
(37 CFR §1.8 a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

June 4, 2001
Date of Delivery

Laura Sullivan
Name of Person Delivering Paper

Laura Sullivan
Signature of Person Delivering Paper

No fee is believed due in connection with this transmittal. However, if any fee is due, kindly charge the appropriate amount to Deposit Account No. 50-1273.

Respectfully submitted,

BROBECK, PHLEGER & HARRISON, LLP

Dated: 6/04/01

By: _____

Edward O. Kreusser
Reg. No. 38,523

Brobeck, Phleger & Harrison LLP
12390 El Camino Real
San Diego, CA 92130
Phone (858) 720-2500
Fax (858) 720-2555

#8

Patent
030727.0044.CPA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Duft, *et al.*

Serial No.: 09/445,517

Filed: June 5, 1998

For: METHOD FOR TREATING OBESITY

Group Art Unit: 1645

Examiner: Devi, S.

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the Applicants' duty under 37 CFR 1.56, Applicants bring to the attention of the Examiner the documents listed on the attached Form PTO-1449. Applicants respectfully request that the documents be made of record in the above-referenced application. Copies of the documents are enclosed for the convenience of the Examiner.

The items identified in this Information Disclosure Statement may or may not be "material" pursuant to 37 CFR 1.56 and the submission thereof by Applicants shall not be construed as an

CERTIFICATE OF MAILING
(37 CFR §1.8 a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

Laura Sullivan
Name of Person Delivering Paper

June 6, 2001
Date of Delivery

Laura Sullivan
Signature of Person Delivering Paper

admission that any such patent, publication or other information referred to therein is material or considered to be material (37 CFR 1.97(h)), or even qualifies as "prior art" under 35 U.S.C. § 102 with respect to this invention unless specifically designated by Applicants as such.

The filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information, as defined in 37 CFR 1.56, exists.

This Information Disclosure Statement is being submitted under 37 CFR 1.97(c) (2). Enclosed is a check in the amount of $180.00 to cover the fee pursuant to 37 CFR 1.17(p). The Commissioner is authorized to charge any additional fee required by this submission or to credit any over payment to counsel's Deposit Account No. **50-1273**.

Respectfully submitted,

BROBECK, PHLEGER & HARRISON, LLP

Dated: 6/4/01

By: _____
Edward O. Kreusser
Reg. No. 38,523

Brobeck, Phleger & Harrison LLP
12390 El Camino Real
San Diego, CA 92130
Phone (858) 720-2500
Fax (858) 720-2555

Please type a plus sign (+) inside this box +

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known	
Application Number	09/445,517
Filing Date	December 6, 1999
First Named Inventor	Duft, et al.
Group Art Unit	1645
Examiner Name	S Devi, Ph.D.
Attorney Docket Number	030639.0044 CPA

Sheet | | of | 5

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MMDDYYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	5,367,052		Cooper, G.J.S.	11/22/94	
	AB	5,175,145		Cooper, G.J.S.	12/29/92	
	AC	5,124,314		Cooper, G.J.S.	6/23/92	
	AD	5,266,561		Cooper, G.J.S.	11/30/93	
	AE	5,264,372		Beaumont, K.	11/23/93	
	AF	5,376,638		Young, A.A.	12/27/94	
	AG	5,656,590		Rink, T.J.	8/12/97	
	AH	5,234,906		Young, A.	8/10/93	
	AI	5,686,411		Gaeta	11/11/97	
	AJ	5,264,372		Beaumont	11/23/93	
	AK	5,280,014		Cooper, G.J.S.	1/18/94	
	AL	5,364,841		Garth, J.S.	11/15/94	
	AM	5,739,106		Rink, T.J.	4/14/98	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	AN		WO 9640220		Kolterman	12/19/96		
	AO		WO 9220367		Rink	11/26/92		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	AP	ALAM *et al.*, "Selective Angatonism Of Calcitonin-Induced Osteoclastic Quiescence (Q Effect) By Human Calcitonin Gene-Related Peptide-(Val^{8}Phe^{37})," Biochem. Biophys.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Unique citation designation number. [2]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known	
Application Number	09/445,517
Filing Date	December 6, 1999
First Named Inventor	Duft, et al.
Group Art Unit	1645
Examiner Name	S Devi, Ph.D.
Attorney Docket Number	030639.0044 CPA

Sheet | | of | 5

		Res. Commun., 179(1):134-139 (1991)	
	AQ	ARNELO, U., et al, "Chronic infusion of islet amyloid polypeptide causes anorexia in rats," Regulatory Integrative and Comparative Physiology 40(6):R1654-R1659 (1996)	
	AR	BEAUMONT et al., "Regulation of muscle glycogen metabolism by CGRP and amylin: CGRP receptors not involved," Br. J. Pharmacol., 115(5):713-715, 1995	
	AS	BRAIN *et al.*, "Amylin Amide, Which Is Structurally Similar To Calcitonin Gene-Related Peptide (Cgrp), Stimulates Increased Blood Flow In Vivo," Eur. J. Pharmacol., 183:2221 (1990)	
	AT	BRAY, G.A., "Drug treatment of obesity," Am J Clin Nutr 55:538S-544S (1992)	
	AU	BRAY, G.A. "Treatment ofr Obesity: A Nutrient Balance/Nutrient Partition Approach," Nutrition Reviews 49:33-45 (1991)	
	AV	BRODERICK et al., "Human and Rat Amylin have no Effects on Insulin Secretion in Isolated Rat Pancreatic Islets," Biochem. Biophys. Res. Commun., 177:932-938, 1991	
	AW	BROWN et al., "The Effects of Amylin on changes in Plasma Glucose and Gastric Emptying Following an Oral Glucose Load in Conscious Dogs," Diabetes, 43 (Suppl 1): 172A, 1994	
	AX	CHANCE et al., "Anorexia following the intrahypothalamc administration of amylin," Brain Res., 539:352-354, 1991	
	AY	CHANCE, W.T., et al, "Anorexia following the systemic injection of amylin," Brain Res. 607:185-188 (1993)	
	AZ	CHANTRY et al., "Cross-reactivity of amylin with calcitonin-gene-related peptide binding sites in rat liver and skeletal muscle membranes," Biochem. J., 277:139-143, 1991	
	BA	COLBURN, et al, "Pharmacokinetics and pharmacodynamics of AC137 (25,28,29 tripro-amylin, human) after intravenous bolus and infusion doses in patients with insulin-dependent diabetes," J Clin. Pharmacol. 36(1):13-24 (1996)	
	BB	COOPER et al., "Amylin and the amylin gene: structure, function and relationship to islet amyloid and to diabetes mellitus," Biochem. Biophys. Acta., 1014:247-258, 1989	
	BC	COOPER et al., "The Amylin Superfamily: A Novel Grouping of Biologically Active Polypeptides Related to the Insulin A-Chain," Prog. Growth Factor Research, 1:99-105, 1989	
	BD	COOPER et al., "Amylin found in amyloid deposits in human type 2 diabetes mellitus may be a hormone that regulated glycogen metabolism in skeletal muscle," Proc. Natl. Acad. Sci., USA, 85:7763-7766, 1988	
	BE	COOPER et al., "Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients," Proc. Natl. Acad. Sci., USA, 84:8628-8632, 1987	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Unique citation designation number. [2]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.
NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box +

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. 0MB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid 0MB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet		of	5

Complete if Known	
Application Number	09/445,517
Filing Date	December 6, 1999
First Named Inventor	Duft, et al.
Group Art Unit	1645
Examiner Name	S Devi, Ph.D.
Attorney Docket Number	030639.0044 CPA

	BF	COOPER et al., "Amylin found in amyloid deposits in human type 2 diabetes mellitus may be a hormone that regulated glycogen metabolism in skeletal muscle," Proc. Natl. Acad. Sci., USA, 85:7763-7766, 1988 (duplicate)	
	BG	DEEMS et al., "Amylin or CGRP (8-37) Fragments Reverse Amylin-induced Inhibition of ^{14}C-Glycogen Accumulation," Biochem. Biophys. Res. Commun., 181(1):116-120, 1991	
	BH	FOLLETT *et al.*, "Effect of Amylin on Insulin receptor Kinase Activity In Vivo in the Rat," Clinical Research, 39(1):39A (1991)	
	BI	GAETA and RINK, "Amylin: A new hormone as a therapeutic target in diabetes mellitus and other metabolic diseases," Med. Chem. Res., 3:483-490, 1994	
	BJ	GALEAZZA et al., "Islet Amyloid Peptide (IAPP) Competes for Two Binding Sites of CGRP," Peptides, 12:585-591, 1991	
	BK	GARDINER et al., "Antagonistic Effect of Human -Calcitonin Gene-Related Peptide (8-37) on Reginal Hemodynamic Actions of Rat Islet Amyloid Polypeptide in Conscious Long-Evans Rats," Diabetes, 40:948-951, 1991	
	BL	GEDULIN et al., "Amylin Secretion from the Perfused Pancreas: Dissociation from Insulin and Abnormal Elevation in Insulin-Resistant Diabetic Rats," Biochem. Biophys. Res. Commun., 180(1):782-789, 1991	
	BM	GEDULIN et al., "Endogenous Amylin and Gastric Emptying in Rats: Comparison with GLP-1 and CCK-8," Diabetologia, 38 (suppl 1): A244 (1995)	
	BN	GOMEZ-FOIX et al., "Anti-insulin effects of amylin and calcitonin-gene-related peptide on hepatic glycogen metabolism," Biochem J., 276:607-610, 1991	
	BO	HUANG et al., "Hyperamylinemia, Hyperinsulinemia, and Insulin Resistance in Genetically Obese LA/N-*cp* Rats," Hypertension, 19:I-101-I-109, 1991	
	BP	JUNG and CHONG, "The Management of Obesity," Clinical Endocrinology 35:11-20 (1991)	
	BQ	KODA et al., "Amylin concentrations and glucose control," The Lancet, 339:1179-1180, 1992	
	BR	KOLTERMAN et al. "Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insuling hallenge and response to a standard liquid meal in patients with IDDM," Diabetologia, 39:492-299, 1996.	
	BS	KOLTERMAN, "Amylin and glycaemic regulation: A possible role for the human amylin analogue pramlintide," Diabetic Med 14(Supp 2):S35-S38 (1997)	
	BT	KOOPMANS et al., "Amylin-induced in vivo insulin resistance in conscious rats: the liver is more sensitive to amylin than peripheral tissues," Diabetologia, 34:218-224, 1991	
	BU	LEIGHTON et al., "Pancreatic amylin and calcitonin gene-related peptide cause	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Unique citation designation number. [2]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.
NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box +

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet		of	5

Complete if Known	
Application Number	09/445,517
Filing Date	December 6, 1999
First Named Inventor	Duft, et al.
Group Art Unit	1645
Examiner Name	S Devi, Ph.D.
Attorney Docket Number	030639.0044 CPA

		resistance to insulin in skeletal muscle *in vitro*," Nature, 335:632-635, 1988	
	BV	LUDVIK, et al, "Amylin: history and overview," Diabet. Med. 14(Supp 2)(1997)(see abstract)	
	BW	LUPIEN et al., "No measureable effect of amylin in lipolysis in either white or brown isolated adipocytes from rats," Diab. Nutr. Metab., 6(1):13-18, 1993	
	BX	LUTZ, et al, "Reduction of food intake in rats by intraperitoneal injection of low doses of amylin," Physiol. Behav. 55(5): 891-895 (1994)	
	BY	MACDONALD et al., "Infusion of the Human Amylin Analogue, AC137 Delays gastric Emptying in Men with IDDM," Diabetologia 38 (suppl 1): A32 (abstract 118) 1995	
	BZ	MOLINA et al., "Induction of Insulin Resistance In Vivo by Amylin and Calcitonin Gene-Related Peptide," Diabetes, 39:260-265, 1990	
	CA	MOORE et al., "Co-Secretion of Amylin and Insulin from Cultured Islet -cells: Modulation by Nutrient Secretagogues, Islet Hormones and Hypoglycemic Agents," Biochem. Biophys Res. Commun., 179(1):1-9, 1991	
	CB	MORLEY, et al, "Amylin decreases food intake in mice," Peptides 12(4):865-869 (1991)	
	CC	MORLEY, et al, "Effects of amylin on appetite regulation and memory," Can. J. Physiol. Pharmacol. 73(7):1042-1046 (1995)	
	CD	MORLEY, et al, "Modulation of food intake by peripherally administered amylin," Am. J. Physiol 267(1)(Pt 2):R178-R184 (1994)	
	CE	MOYSES, et al "Modulation of gastric emptying as a therapeutic approach to glycaemic control," Diabetic Medicine 13(5)(Supp 1): S34-S38 (1996)	
	CF	NOWAK et al. "Accelerated gastric emptying in diabetic rodents: Effect of insulin treatment and pancrease transplantation," J. Lab. Clin. Med., 123(1):110-6, 1994	
	CG	PITTNER et al., "Amylin and epinephrine have no direct effect on glucose transport in isolated rat soleus muscle," FEBS Letts., 365(1):98-100, 1995	
	CH	PITTNER et al., "Molecular Physiology of Amylin," J. Cell. Biochem., 55S:19-28, 1994	
	CI	PLOURDE et al., "CGRP 8-27 Blocks the Inhibition of Gastric Emptying Induced by Intravenous Injection of -CGRP in Rats," Life Sci. 52:857-862, 1993	
	CJ	RINK et al., " Structure and biology of amylin," Trends In Pharmaceutical Sciences (TIPS), 14:113-118, 1993	
	CK	RODEN et al., "Effect of islet amyloid polypeptide on hepatic insulin resistnace and glucose production in the isolated perfused rat liver," Diabetologia, 35:116-120, 1992	
	CL	ROWLAND et al. "Potential Role of Neuropeptide Ligands in the Treatment of Overeating," CNS Drugs, 7(6):419-420, 1997	
	CM	STEPHENS et al.,"Presence of Liver CGRP/Amylin Receptors in Only Nonparenchymal Cells and Absence of Direct Regulation of Rat Liver Glucose Metabolism by	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Unique citation designation number. [2]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U, S. Patent and Trademark Office, Washington, DC 20231. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box +

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet		of	5

Complete if Known	
Application Number	09/445,517
Filing Date	December 6, 1999
First Named Inventor	Duft, et al.
Group Art Unit	1645
Examiner Name	S Devi, Ph.D.
Attorney Docket Number	030639.0044 CPA

		CGRP/Amylin," Diabetes, 40:395-400, 1991	
	CN	THOMPSON, R.G., et al, "Effects of Pramlintide, an Analog of Human Amylin, on Plasma Glucose Profiles in Patients with IDDM," Diabetes 46:632-636 (1997)	
	CO	WANG et al., "$^{8-37}$h-CGRP antagonizes actions of amylin on carbohydrate metabolism in vitro and in vivo," FEBS Letters, 291(2):195-198, 1991	
	CP	WEISER, et al, "The pharmacologic approach to the treatment of obesity," J Clin. Pharmacol. 37(6):453-473 (1997)	
	CQ	YOUNG et al., "Amylin and insulin in rat soleus muscle: dose responses for cosecreted noncompetitive antagonists," Am. J. Phys., 263(2):E274-E281, 1992	
	CR	YOUNG et al., "Effects of amylin on glucose metabolism and glycogenolysis in vivo and in vitro," Am. J. Physiol., 259:E457-E461, 1990	
	CS	YOUNG et al., "Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin," Diabetologia, 38(6):642-648, 1995	
	CT	YOUNG, A.A., et al, "Preclinical Pharmacology of Pramlintide in the Rat: Comparisons with Human and Rat Amylin," Drug Development Research 37: 231-248 (1996)	
	CU	YOUNG et al., "Amylin activates glycogen phosphorylase in the isolated soleus muscle of the rat," FEBS Letters, 281(1,2)149-151, 1991	
	CV	YOUNG et al., "$^{8-37}$hCGRP, an amylin receptor antagonist, enhances the insulin response and perturbs the glucose response to infused arginine in anesthetized rats," Mol. Cell Endocrino., 84:R1-R5, 1992	
	CW	ZAIDI, et al, "Amylin in Bone Conservation Current Evidence and Hypothetical Considerations," Trends in Endocrinal. and Metab. 4:255-259 (1993)	
	CX	ZHU et al., "Amylin Increases Cyclic Amp Formation in L6 Myocytes through Calcitonin Gene-Related Peptide Receptors," Biochem Biophys. Res. Commun., 177(2):771-776, 1991	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Unique citation designation number. [2]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U, S. Patent and Trademark Office, Washington, DC 20231. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.